We are live on ! Find out more
DSGN icon

Design Therapeutics
DSGN

100 hedge funds and large institutions have $172M invested in Design Therapeutics in 2024 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 30 increasing their positions, 34 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 1 → 2 (+1)

60% more capital invested

Capital invested by funds: $108M → $172M (+$64.8M)

56% more first-time investments, than exits

New positions opened: 14 | Existing positions closed: 9

5% more funds holding

Funds holding: 95 → 100 (+5)

0.24% less ownership

Funds ownership: 56.81% → 56.57% (-0.24%)

12% less repeat investments, than reductions

Existing positions increased: 30 | Existing positions reduced: 34

90% less call options, than puts

Call options by funds: $18K | Put options by funds: $175K

Holders
100
Holders Change
+5
Holders Change %
+5.26%
% of All Funds
1.44%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.03%
New
14
Increased
30
Reduced
34
Closed
9
Calls
$18K
Puts
$175K
Net Calls
-$157K
Net Calls Change
-$87K

Top Buyers

1
Fidelity Investments
Fidelity Investments
Massachusetts
+$3.52M
2
FLSM
Frazier Life Sciences Management
California
+$3.28M
3
Point72 Asset Management
Point72 Asset Management
Connecticut
+$2.87M
4
Citadel Advisors
Citadel Advisors
Florida
+$1.27M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$457K

Top Sellers

1
LGM
Logos Global Management
California
-$3.83M
2
Millennium Management
Millennium Management
New York
-$1.9M
3
Goldman Sachs
Goldman Sachs
New York
-$1.54M
4
BCM
BML Capital Management
Indiana
-$1.41M
5
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$922K
Name Holding Trade Value Shares
Change 		Change in
Stake
BCM
26
Bridgeway Capital Management
Texas
$1.27M – – –
N
27
Nuveen
North Carolina
$1.14M – – –
Millennium Management
28
Millennium Management
New York
$1.12M -$1.9M -403,546 -66%
GCP
29
GSA Capital Partners
United Kingdom
$935K -$170K -36,209 -17%
Dimensional Fund Advisors
30
Dimensional Fund Advisors
Texas
$723K +$251K +53,407 +66%
Bank of New York Mellon
31
Bank of New York Mellon
New York
$533K -$89.3K -18,985 -16%
Barclays
32
Barclays
United Kingdom
$520K +$116K +24,602 +34%
Squarepoint
33
Squarepoint
New York
$458K -$22.7K -4,824 -5%
Walleye Capital
34
Walleye Capital
New York
$377K +$46K +9,788 +16%
Prudential Financial
35
Prudential Financial
New Jersey
$318K -$19.3K -4,100 -6%
EC
36
EcoR1 Capital
California
$290K +$253K +53,834 New
RhumbLine Advisers
37
RhumbLine Advisers
Massachusetts
$272K -$11.8K -2,500 -5%
VF
38
Virtu Financial
New York
$249K +$166K +35,286 +319%
Ameriprise
39
Ameriprise
Minnesota
$233K -$34.2K -7,270 -14%
AllianceBernstein
40
AllianceBernstein
Tennessee
$226K – – –
JP Morgan Chase
41
JP Morgan Chase
New York
$219K +$125K +26,503 +187%
Bank of America
42
Bank of America
North Carolina
$198K +$21.3K +4,527 +14%
PWM
43
Palumbo Wealth Management
New York
$198K +$17.5K +3,720 +11%
PP
44
PDT Partners
New York
$194K +$42.2K +8,972 +33%
American Century Companies
45
American Century Companies
Missouri
$176K +$53.1K +11,301 +53%
SO
46
STRS Ohio
Ohio
$175K – – –
HSBC Holdings
47
HSBC Holdings
United Kingdom
$168K -$62K -13,183 -30%
Deutsche Bank
48
Deutsche Bank
Germany
$151K – – –
Corient Private Wealth
49
Corient Private Wealth
Florida
$145K – – –
SA
50
SpiderRock Advisors
Delaware
$145K +$127K +26,965 New
1
2
3 4 5

DSGN Hedge Fund Activity: Q3 2024 in Review

100 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q3 2024, worth a combined $172M — up 60% from $108M a quarter earlier.

Buyers outnumbered sellers: 14 funds opened new DSGN positions and 9 closed out — a net gain of 5 holders — while 30 added to existing stakes and 34 trimmed.

The largest buyer was Fidelity Investments, adding an estimated $3.52M. The largest seller was Logos Global Management, cutting an estimated $3.83M.

  • 100 institutional investors held Design Therapeutics (DSGN) as of Q3 2024, up from 95 in Q2 2024.
  • Funds reported $172M of Design Therapeutics stock for Q3 2024, up 60% quarter-over-quarter.
  • 14 funds opened new Design Therapeutics positions in Q3 2024 and 9 closed out, a net change of +5 holders.
  • The largest Design Therapeutics buyer in Q3 2024 was Fidelity Investments, an estimated $3.52M added.
  • The largest Design Therapeutics seller in Q3 2024 was Logos Global Management, an estimated $3.83M sold.

Based on aggregated 13F filings for Q3 2024.